Opportunistic Infections

Dr. Edmund Wilkins

Head of the HIV Clinical Trials Unit
North Manchester General Hospital

GreenShoots FOUNDATION

“Support needing populations through medical assistance and the transfer of knowledge to local medical practitioners.”

Our vision for the

Medical Assistance & Medical Education (MAME) Programs

GreenShoots FOUNDATION


FISHER S
A-587-59
PANY




FH 22 head






SE/M
SL12



Outline

- Background

- Today I will break it down:
  - Review of many of the OI's
  - Focus on the main clinical challenges
  - Present recent data

- Please interrupt……

In the West! HOPS Cohort: Late presentation and opportunistic infections (OIs)

- With the advent of cART and routine use of antimicrobial prophylaxis, the rates of AIDS-defining OIs among HIV-infected have declined dramatically
- Nonetheless, OIs remain a leading cause of hospitalization and death among late presenting patients



- A third of OIs were diagnosed at CD4 ≤200 cells/mm^3

Adapted from Buchacz K et al., *AIDS* 2010, 24:1549–1559.

Often difficult to diagnose



May be part of multiple infections requiring treatment







Risk of opportunistic infections by CD4 count



Adapted from Battegay M et al., *Antivir Ther* 2007, 12:841–851.

Guidelines exist..


A


B


C


D


E


F


G


H


OI’s in the Brain

Patient 1

- 37-year male from SSA
- **Headaches and fever for 2w**
- **Focal fit at work Jan 2009**
- HIV +ve
- **CD4 102**
- Further focal fits
- **Mild weakness left lower limb**

What is your diagnosis?

1. Cerebral Abscess
2. Primary CNS lymphoma
3. Cerebral toxoplasmosis
4. Tuberculoma
5. Cryptococcoma

Audience vote

Patient 1

- 37-year male from SSA
- **Headaches and fever for 2w**
- **Focal fit at work Jan 2009**
- HIV +ve
- **CD4 102**
- Further focal fits
- **Mild weakness left lower limb**



Patient 1

- 37-year male from SSA
- **Headaches and fever for 2w**
- **Focal fit at work Jan 2009**
- HIV +ve
- **CD4 102**
- Further focal fits
- **Mild weakness left lower limb**
- **MR scan performed**



Clinical challenges with toxoplasmosis

A. Diagnosis without/with scans
B. Optimal treatment
C. Steroids and biopsy
D. Persistent changes on scan
E. When to start ART
F. Distinguishing relapse from IRS

1. Diagnosing cause – clinical toxoplasmosis

CLINICAL FEATURES			
	TOXOPLASMOSIS	**PCNSL**	**PML**
Presentation	**Headache, focal fits, fever, drowsy, focal neurology**	**Confusion, focal neurology**	**Visual/speech defects, focal neurology**
Seizures	**33%**	**15%**	**Uncommon**
Clinical history	**<2 weeks**	**2-8 weeks**	**Weeks to months**
CD4 count	**<100**	**<50**	**<50**
Other	**Retinitis may coexist** **Rarely encephalitic process**	**No evidence of disease outside of brain**	

1. Diagnosing cause - imaging

MR FEATURES			
	PCNSL		TOXOPLASMOSIS
Number			Usually multiple
Enhancement			Prominent Ring
Oedema			Marked
Location			Basal ganglia Brain stem Cortical
			Interface grey-white matter
MR T1			Low signal
MR T2			High signal

1. Differential diagnosis
Primary CNS lymphoma

CLINICAL FEATURES			
	Primary CNS Lymphoma	**Toxoplasmosis**	**PML**
Presentation	**Confusion, focal neurology, no fever**	**Confusion, focal neurology**	**Visual/speech defects, focal neurology**
Seizures	**15%**	**15%**	**Uncommon**
Clinical history	**2-8 weeks**	**2-8 weeks**	**Weeks to months**
CD4 count	**<50**	**<50**	**<50**
Other	**No evidence of disease outside of brain**	**No evidence of disease outside of brain**	

1. Differential diagnosis - PCNSL

MR FEATURES			
	PCNSL		SMOSIS
Number	Single-few		ultiple
Enhancement	Prominent Homogeneous		nent g
Oedema	Mild-moderate		ed
Location	Periventricular		anglia stem cal
	Anywhere		rey-white er
MR T1	Low to isodense		gnal
MR T2	Variable		High signal



1. Differential diagnosis - PML

CLINICAL FEATURES			
	PML	**Toxoplasmosis**	**PCNSL**
Presentation	**Visual/speech defects, focal neurology**	**Confusion, focal neurology**	**Confusion, focal neurology**
Seizures	**Uncommon**	**15%**	**15%**
Clinical history	**Weeks to months**	**2-8 weeks**	**2-8 weeks**
CD4 count	**<50**	**<50**	**<50**
Other	**No evidence of disease outside of brain**	**Retinitis may coexist** **Rarely encephalitic process**	**No evidence of disease outside of brain**

1. Differential diagnosis - PML

MR FEATURES			
	PML		TOXOPLASMOSIS
Number	Single-multiple		Usually multiple
Enhancement	Nil		Prominent Ring
Oedema	Nil		Marked
Location	Occipitoparietal		Basal ganglia Brain stem Cortical
	White matter		Interface grey-white matter
MR T1	Low signal		Low signal
MR T2	High signal		High signal



Advice given for immediate management options

1. Treat for toxoplasmosis
2. Defer treatment and get CSF
3. Refer to unit where they can do urgent brain biopsy
4. Treat for TB
5. Treat for toxoplasmosis and give steroids
6. Other

Audience vote

Patient with toxoplasmosis after 2w toxoplasma treatment



Back to our patient post treatment at 8w



Patient with PCNSL after 2w toxoplasma treatment



Additional imaging

- 201 Thallium SPECT
- 18FDG-PET (positron emission scanning):
  - Lesions show increased uptake
  - Toxoplasmosis lesions are metabolically inactive



- Brain biopsy

^{18}FDG-PET



2. Diagnosing cause - the CD4 count

- 28yr old Zimbabwean lady
- In UK for 3 years
  - Diagnosed HIV +ve at antenatal screening
  - Currently on EFV/TDF/FTC
  - **CD4 876, VL <40 c/ml**
- **Admitted after having 2 GM convulsions at home**
  - No history of fits or other neurological problems, TB



What is your diagnosis?

1. Cerebral Abscess
2. Primary CNS lymphoma
3. Cerebral toxoplasmosis
4. Tuberculoma
5. Cryptococcoma
6. Other

Audience vote

2. Diagnosing cause - the CD4 count

- 28yr old Zimbabwean lady
- In UK for 3 years
  - Diagnosed HIV +ve at antenatal screening
  - Currently on EFV/TDF/FTC
  - **CD4 876, VL <40 c/ml**
- **Admitted after having 2 GM convulsions at home**
  - No history of fits or other neurological problems, TB



The importance of the CD4..

CD4 876 cells/µl





Neurocystercicosis..

Serology strongly +ve T. Solium CC

- Started anti-convulsants
- Treated with:
  - Steroids 5d
  - Albendazole 14d

- No real association with HIV
- **Can occur at any CD4**

LESSON: THINK NON-HIV IF HIGH CD4

The importance of the CD4 count and a brain biopsy

- Known HIV +ve
  - **CD4 333**
- **Admitted 2w hx of ↑ psychosis**
  - **CRAG -ve**
  - **CSF 84 LC: protein 1.2, no growth**
- Treatment:

What is your diagnosis?

1. TB meningitis
2. Cryptococcal meningitis
3. Listeria meningitis
4. Viral meningitis
5. Toxoplasmosis
6. Other

Audience vote

The importance of the CD4 count and a brain biopsy

- Known HIV +ve
  - **CD4 333**
- **Admitted 2w hx of ↑ psychosis**
  - **CRAG -ve**
  - **CSF 84 LC: protein 1.2, no growth**
  - PCR's -ve
- Treatment:
  - Acyclovir, Ceftriaxone
  - TB treatment (RBT), steroids 4w
  - DAR/r/TDF/FTC
- No improvement clinically
  - CSF 230 mixed; protein 1.4

The importance of the CD4 count and a brain biopsy

- Known HIV +ve
  - **CD4 333**
- **Admitted 2w hx of ↑ psychosis**
  - **CRAG -ve**
  - **CSF 84 LC: protein 1.2, no growth**
  - PCR's -ve
  - MR: Meningeal thickening
- Treatment:
  - Acyclovir, Ceftriaxone
  - TB treatment (RBT), steroids 4w
  - DAR/r/TDF/FTC
- No improvement clinically
  - CSF 230 mixed; protein 1.4
- **MR scan after 3 weeks**



Thought to be mad?

Remember CD4 333

- TB treatment intensified
- Toxoplasma treatment started:
  - SD and pyrimethamine/FA
  - No improvement MR scan
- Neurosurgeons biopsied



What is your diagnosis?

1. Cerebral toxoplasmosis
2. Cryptococcoma
3. Candida brain abscess
4. Cerebral aspergillosis
5. Tuberculosis

Audience vote

The importance of the CD4 count and a brain biopsy

Remember CD4 333

- TB treatment intensified
- Toxoplasma treatment started:
  - SD and pyrimethamine/FA
  - No improvement MR scan
- Neurosurgeons biopsied



- Culture: Aspergillus *fumigatus*



- Started Voriconazole

After 12w of antifungal treatment..





3. Diagnosing cause - serology and CSF?

- Toxoplasmosis IgG antibody:
  - +ve 20-80% depending on age and regional exposure
  - 1% seroconversion annually
  - Up to 15% may be IgG antibody -ve

- Toxoplasma PCR CSF:
  - Sometimes not possible because of ↑ ICP
  - Sensitivity 95% specificity 95%

What treatment would you start?

- Co-trimoxazole
- Pyrimethamine and sulphadiazine
- Pyrimethamine and clindamycin
- Atovaquone
- Azithromycin and Atovaquone
- Other

Audience vote

B. What is optimal treatment

- 2 RCT comparing SUL/PYR vs. CLIND/PYR 6w

N=	59		292	
	Clind/Pyr	Sulph/Pyr	Clind/Pyr	Sulph/Pyr
Response (%)	65	70	68	76
Toxicity D/C (%)	23	33	11	30

- Other small RCT confirm activity of:
  - ATOV or AZITH or CLARITH/AZITHRO or DOXY or DAPSONE with PYR and FOL
  - ATOV and SULP or Minocycline or alone

What is optimal treatment

- Overall risk of progression higher in patients receiving PM-CM than PM-SD.
- No difference during acute therapy
- Relapse rate twice as high
- Toxicity rates less with PM-CM
- Studies mainly pre-ART

Overall progression of disease



PM/SD = pyrimethamine/sulphadiazine
PM/CM = pyrimethamine/clindamycin

Co-trimoxazole as 2nd line

- Single randomized controlled study of CTX
  - 40 received CTX
  - 37 received PYR-SULPH
- PYR-SULPH and CTX were equivalent with respect to clinical and radiological efficacy
  - **85.7% vs. 83.7% and 69.6% vs. 72.9%**
- However, tolerability significantly better in the CTX group
  - 5 events in the CTX group vs. 14 events in the PYR-SULPH group)
- Two single arm cohort studies have repeated these results for CTX

Toxoplasmosis – treatment

- Repeat imaging after 2-4w therapy of pyrimethamine/folinic acid with either sulphadiazine or clindamycin
- Clinical improvement:
  - 50% at 5d, 70% at 7d and 90% at 14d of toxoplasma treatment
  - Failure to improve at 2w indicates likely PCNSL
- MRI improvement:
  - Seen by 2-4w

Do you advise steroids?

- Always
- Only when significant localising signs
- Only when oedema (if you can get scan)
- Never
- Only if deteriorates on treatment
- Other

Audience vote

C. What is the place of brain biopsy & steroids?

- Consider brain biopsy when:
  - **Empiric therapy fails**
  - There is a reliable history of co-trimoxazole prophylaxis
  - Patients receiving steroids relapse on tailing off
  - **There is a single atypical lesion,**
  - The CD4 count is >200 cells/mL

Biopsy diagnosis = TB



What is the place of brain biopsy & steroids?

- Dexamethasone indicated:
  - If features of significant raised ICP or midline/ tentorial shift
  - Dexamethasone 4mg qds tapering dose
  - **Can cloud diagnosis and management**
  - **Clinical deterioration after tailing off steroids usually indicates urgent need for brain biopsy**



D. How to manage persistent changes on scan/persistent neurology

- Heterosexual man presents with:
  - Convulsions, fever, localising signs
  - Diagnosed as bacterial abscess
  - 3w before HIV diagnosed and toxoplasmosis treated
- Started ART at 3 weeks
- Now CD4 >350



Progress at 4 and 8 weeks – biopsy showed ‘inflammation’





At 6 months – biopsy reviewed





- **Where a diagnosis is uncertain – consider biopsy**
- **Changes may take years to resolve or never do so**

When would you start ART?

- Immediately
- When established on toxoplasma therapy
- Around 2 weeks
- After discontinuing toxoplasma treatment at around 6w
- Not before 3 months

Audience vote

Starting HAART: ACTG 5164: Immediate vs. deferred in patients with acute OIs (not TB)

- Immediate treatment group had reduced rate of AIDS progression or death (14.2%) compared with deferred treatment group (24.1%)
- No differences in IRIS between arms (10 immediate vs. 13 deferred)
  - However, 70% of patients with PCP received corticosteroids
- The most common OIs were PCP (63%), Cryptococcus (12%), BI (bacterial infection (11%)), *TB excluded*

Immediate ART: initiation within 48h of randomization and within 14 days of starting OI treatment
Deferred ART: initiation between weeks 4 and 32



Adapted from Zolopa A, et al. CROI 2008, Boston, MA, USA, Abstract 142

E. Distinguishing relapse from IRS



Pre-treatment

Week 1

Week 6 (3w after ARV)

Distinguishing relapse from IRS

- IRS with ART
  - Uncommon
  - Adherence good
  - 4-8w after starting ART
  - Rapid CD4 rise
  - Significant oedema
- Biopsy may be required
- Treatment steroids

Patient 2

- 41y old male
- Poor adherence HAART
- **CD4 30-70**
- **Severe headache,** tiredness 2-3 weeks
- Occasional double vision
- No localising signs, no neck stiffness



What is your diagnosis?

1. TB meningitis
2. Cryptococcal meningitis
3. CMV encephalitis
4. Viral meningitis
5. Toxoplasmosis
6. Tuberculoma
7. Primary CNS lymphoma

Audience vote

Patient 2

- 41y old male
- Poor adherence HAART
- **CD4 30-70**
- **Severe headache,** tiredness 2-3 weeks
- Occasional double vision
- No localising signs, no neck stiffness
- CSF
  - Protein 0.8, glucose 2.1
  - Lymphocytes 85, RBC 5
  - **India ink +ve, culture cryptococcus**
  - **Pressure 32 mmHg**
- CT scan



Patient 2

- 41y old male
- Poor adherence HAART
- CD4 30-70
- Severe headache, tiredness 2-3 weeks
- Occasional double vision
- No localising signs, no neck stiffness
- MR scan
- CSF
  - Protein 0.8, glucose 2.1
  - Lymphocytes 85, RBC 5
  - **India ink +ve, culture cryptococcus**
  - **Pressure 32 mmHg**



Symptoms + CSF parameters

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Combination Antifungal Therapy for Cryptococcal Meningitis

Duration of symptoms — days‡			
Median	15	14	12
Interquartile range	7–22	8–18	7–20
Headache — no./total no. (%)	95/97 (98)	99/99 (100)	98/99 (99)
Fever — no./total no. (%)	75/97 (77)	75/98 (77)	72/98 (73)
Neck stiffness — no./total no. (%)	66/91 (73)	64/91 (70)	66/95 (69)
Seizure — no./total no. (%)	9/94 (10)	9/98 (9)	2/98 (2)
Glasgow Coma Scale score — no./total no. (%)§			
15	66/97 (68)	67/99 (68)	78/98 (80)
11–14	21/97 (22)	24/99 (24)	15/98 (15)
≤10	10/97 (10)	8/99 (8)	5/98 (5)
Cranial-nerve palsy — no./total no. (%)	27/97 (28)	22/98 (22)	18/98 (18)
Papilledema — no./total no. (%)	18/85 (21)	19/89 (21)	17/93 (18)
CSF opening pressure >18 cm of CSF — no./total no. (%)	56/83 (67)	61/80 (76)	55/81 (68)
CSF white-cell count — cells/ml¶			
Median	33	26	24
Interquartile range	7–76	8–61	7–83

Cryptococcal and TB meningitis

	Cryptococcal meningitis		TB meningitis
Presentation	**Headache**, fever, drowsy, confusion, eye symptoms		Headache, fever, confusion, CN palsies, neck stiffness
Seizures	15%		15%
Clinical history	<4 weeks		1-8 weeks
Masses	Rare Single		Uncommon May be multiple
Enhancement	Marked meninges		Marked basal meninges
Hydrocephalus	Occasional		Occasional
Location masses	Basal ganglia		Anywhere

Cryptococcal meningitis

	Cryptococcal meningitis	TB meningitis
Other features	**Lymphocytes** **High protein** **India ink +ve** **CRAG +ve**	Lymphocytes AFB rarely +ve PCR +ve CXR +ve





Clinical challenges

A. Raised ICP
B. Persistence vs. relapse vs. IRS
C. Optimal treatment
D. Fluconazole resistance
E. When to start ART
F. CRAG +ve and asymptomatic

A. Raised ICP







A. Raised ICP

- **Always** measure opening pressure at LP
  - If opening pressure > 25 cm H2O drain until < 20cm or 50% of initial pressure
  - Repeat daily until stable
  - Always consider repeat LP on patient who deteriorates or develops new neurological signs
  - In resistant cases consider lumbar drain or VP shunt
  - No evidence for benefit from steroids or acetazolamide
  - Higher burden CRY gives higher pressures

LESSON: LP – CRAG and pressure

What treatment would you start?

1. Fluconazole alone
2. Amphotericin B & 5-flucytosine
3. Amphotericin B & fluconazole
4. Voriconazole alone
5. Fluconazole & 5-flucytosine
6. Amphotericin and itraconazole

Audience vote

Optimal treatment

AmpB
vs. AmpB/ 5FU
vs. AmpB/FLU





Our patient

- After 3w therapy with AMP-B and high-dose FLU and then oral therapy for 1 week
- Readmitted:
  - India Ink +ve
  - Protein decreased to 0.6
  - WCCT 43 cells/ml

What would you do?

1. Restart same dose of same therapy
2. Give higher dose AMP-B
3. Give 5FU with AMP-B
4. Await CSF culture
5. Give steroids
6. Start ART

Audience vote

B. Persistence vs. Relapse vs. IRS

- Persistence:
  - **≥4w still positive culture despite therapy**
  - Usually due to suboptimal induction therapy
  - India Ink and CRAG titre no help
- Relapse:
  - **Return of +ve culture after negative cultures** from sterile site (CSF)
  - And usually return of symptoms/signs

B. Persistence vs. Relapse vs. IRS

Persistence

- **Reinstitute induction therapy**
- Consider increasing AMPB or FLU dose or duration of induction phase
- Check changes in MIC as fluconazole resistance may have developed
- Consider alternative combinations

Relapse

- **Restart induction therapy**
- Check changes MIC for fluconazole resistance
- Consider higher dose of maintenance drug

B. Persistence vs. Relapse vs. IRS

IRS

- Unmasking and paradoxical
- Varies in severity
- Identical presentation to relapse
- Associations:
  - presenting diagnosis, low CD4, high CRAG titre, lack of previous ART, rapid decrease in VL
  - Negative CSF culture
  - Higher cell count

Management

- **Exclude active CRY disease**
- **Continue CRY treatment**
- **Continue ART**
- **Consider steroids in severe disease**
- **Monitor ICP**

Cryptococcal IRS

- IRS: 25%
- Associated with:
  - CRAG +ve
  - Culture +ve
  - Faster CD4 rise



D. Fluconazole resistance

- Where possible isolates should be sent for MIC testing
  - <16 = susceptible
  - 16-32 = susceptible at high doses (many would consider using alternative azole)
  - >64 = resistant
- Relapsing disease
  - N=30
  - Majority developed fluconazole resistance



E. When to start ART?

- Immediately <72 hours
- As soon as the patient is stabilised <2w
- At the end of induction therapy = 2w
- When the India ink stain becomes negative
- When the CSF pressure is normal
- When the CSF is culture negative
- At the end of maintenance treatment = 8w
- Other

Audience vote

When to start? Decreased survival rate starting early

- N = 177
- Arms randomised to start therapy at 1-2w or 5w
- Induction treatment AMP-B/ FLU 800mg for 2w
- Consolidation therapy FLU
- Early ART resulted in higher mortality HR 1.73 (1.62-2.83)
- Associated with fewer CSF white cells at BL





E. When to start? Increased survival rate starting early

- N = 501
- Meta-analysis
- Multiple sites
- Mortality
  - 17% at 2w
  - 34% at 4w
- IRS no association with
  - Death
  - ART timing



F. CRAG +ve and asymptomatic

- Check blood and CSF cultures
- If culture +ve give full treatment and then secondary prophylaxis
- If culture –ve,
  - Either maintain on fluconazole prophylaxis until immune reconstitution
  - Or treat with full dose fluconazole

Patient

- 39y old diagnosed 2004
- Not seen clinic for many years
  - No HAART
  - **Rapid dementing / encephalopathy illness**
  - **CD4 14**, viral load 2 million, **CRAG -ve**
- Admitted:
  - CSF 320 white cells
  - Raised protein

What is your diagnosis?

1. TB meningitis
2. Cryptococcal meningitis
3. CMV encephalitis
4. Viral meningitis
5. Toxoplasmosis
6. Tuberculoma
7. Primary CNS lymphoma

Audience vote

CMV encephalitis

- 39y old diagnosed 2004
- Not seen clinic for many years
  - No HAART
  - Rapid dementing / encephalopathy illness
  - CD4 14, viral load 2 million
- Admitted:
  - CSF CMV-PCR +ve
- Prognosis poor



CMV encephalitis

- Rapid and progressive disorientation, withdrawal, apathy, cranial nerve palsies, and nystagmus
- MR:
  - Bilateral, periventricular enhancement on contrast enhanced T1-weighted scans,
  - Ventricular enlargement,
  - Diffuse white matter change, and subendymal and cortical enhancing lesions
  - May be normal and often non-specific
- CSF:
  - Usually cellular
  - Positive CMV PCR

CMV Polyradiculitis

- 30y old man diagnosed 2000 - CD4 36
- Presentation:
  - Progressive balance problems
  - Unable to bend over without fall over
  - Abnormal gait
  - Difficulty climbing the stairs
  - Bladder / bowel function normal
- Examination:
  - Reduced tone both legs; Reflexes reduced knee/absent ankle
  - Power 4/5 knee and ankle symmetrically
  - Sensation absent:L4-S1







CMV polyradiculitis

- Presentation:
  - Rapidly progressive, painful, bilateral ascending flaccid paralysis
  - Areflexia
  - Saddle anaesthesia
  - Sphincter dysfunction and urinary retention.
- MR
  - Diffuse enhancement of cord parenchyma, nerve roots and meninges
- CSF - PMN pleocytosis and PCR +ve.
- NCS - Axonal neuropathy.


18-08-01
OI's in the lungs

Patient 4

- A 22yr old African man presents with a 10 day history of profound breathlessness, dry cough and fever in December
- Auscultation is unremarkable.
- Investigations:
- Rapid HIV Ab +ve
- Saturation 89% on air
- pO2 7.6 kPa, pCO2 3.9kPa
- CXR as shown
- **Clinical diagnosis PCP**



Challenges

A. Confirmatory diagnosis
B. 2nd line therapy for severe disease
C. CMV co-infection
D. PCP IRS
E. DPHS mutations

A. Confirmatory diagnosis

- Confirmation - PCR or histochemical/fluorescent stains
- Yield: Induced sputum (50-90%), BAL (90-95%), trans-bronchial biopsy (>90-95%)







Patient 4

- High dose IV co-trimoxazole and steroids are commenced
- Subsequent BAL is positive for pneumocystis and CMV on staining.

- Over the next 4 days he deteriorates and is intubated and ventilated

- At 7 days there is no progress

Patient 4



Day 1 - Day 4

Which alteration to his therapy would be most appropriate?

- Add ganciclovir
- Switch/add caspofungin
- Change/add pentamidine
- Switch to clindamycin/primaquine
- Start dapsone/trimethoprim
- Add trimetrexate

Vote ☺

PCP - treatment

- 2nd line:
  - Clindamycin and primaquine (mild to severe)
    - AE: metHB (< with 15mg primaquine), rash
  - Pentamidine (severe)
    - AE: nephrotoxicity, hypotension, hypoglycaemia
  - Trimetrexate (severe)
  - Caspofungin
  - Trimethoprim and dapsone (mild to moderate)
  - Atovaquone (mild)
  - Consider overlap for 48hrs where not toxicity
- HAART commencement/optimisation

C. CMV co-infection

- N=84
- Cohort analysis
- No difference on 21d mortality
- Significant difference at 6m



When would you start HAART?

- Immediately
- After 1-2 week when stable
- When switching to prophylaxis
- At OPD follow-up
- At 3 months

Vote ☺

D. When to start ART: ACTG 5164: Immediate vs. deferred in patients with acute OIs (not TB)

- Immediate treatment group had reduced rate of AIDS progression or death (14.2%) compared with deferred treatment group (24.1%)
- No differences in IRIS between arms (10 immediate vs. 13 deferred)
  - However, 70% of patients with PCP received corticosteroids
- The most common OIs were PCP (63%), Cryptococcus (12%), BI (bacterial infection (11%)), *TB excluded*

Immediate ART: initiation within 48h of randomization and within 14 days of starting OI treatment
Deferred ART: initiation between weeks 4 and 32



Adapted from Zolopa A, et al. CROI 2008, Boston, MA, USA, Abstract 142

E. DHPS mutations and COT resistance

- What about PJP cotrimoxazole resistance?
  - DHPS mutations associated with past prophylaxis
  - Frequency falling as less COT prophylaxis
  - Variable evidence associated with failure of prophylaxis and worse outcome


Disseminated OIs

Patient 5

- On admission:
- Chronic diarrhoea
- Weight loss (>1 stone)
- Examination:
  - Wasted, dehydrated
  - 38^{o}C, tachycardia
- Standard laboratory tests unremarkable
- USS abdomen – normal
- Stool: non- typhi Group D salmonella isolated



Investigations

- BAL:
  - Negative for PCP, AFB, Gram
  - Negative for standard bacterial culture
  - Yeasts identified on initial Gram and presumed to be Candida colonisation
  - No evidence of pulmonary KS
- Ear lesion noted
- **Treated as PCP**
  - **Started co-trimoxazole**




MYANMAR (BURMA)
CHIANG RAI
CHIANG MAI
DOI INTHANON (2590 M)
LAMPANG
SUKHOTHAI
MAE SOT
YANGON (RANGOON)
LAOS
VIENTIANE
MEKONG RIVER
UDON THANI
Thailand
UBON RATCHATHANI
AYUTHAYA
NAKHON PATHOM
BANGKOK
CHACHOENGSAO
KO SI CHANG
PATTAYA
CAMBODIA
KO SAMET
PHNOM PENH
HO CHI MINH CITY (SAIGON)
ANDAMAN SEA
GULF OF THAILAND
KO PHA-NGAN
KO SAMUI
VIETNAM
SURAT THANI
KRABI
NAKHON SI THAMMARAT
PHUKET
HAT YAI
SONGKHLA
SUNGAI KOLOK
INDIAN OCEAN
THALEH BAN NATIONAL PARK
MALAYSIA
0
200km

Thailand

What is your diagnosis?

- PCP
- Miliary TB
- Influenza pneumonitis
- Cryptococcal pneumonia
- Penicillium
- Histoplasma

Audience vote

Investigations

- Biopsy ear:
  - Penicillium marneffei
  - blood, throat swab, ear swab, and BAL all +ve
- Treatment:
  - Liposomal amphotericin (4mg/kg/day)
  - Co-trimoxazole prophylaxis







Penicillium marneffei

Fever	99
Anaemia	78
Weight loss	77
Skin lesions	70
Generalised LN	58
Hepatomegaly	51
Cough	49
Diarrhoea	23

Specimen	Isolation rate
Bone marrow	100
Skin lesion	90
Blood	76
Sputum	34
Lymph node	23
Liver	17
Lung	14

Penicillium marneffei

Treatment	Amphotericin B (0.6-1g/day) for 2 weeks (± 5 FC), *then* Itraconazole 200mg BD for 10 weeks (consider IV Itraconazole if severe)
Maintenance	Itraconazole 200mg OD

Patient 6

- 29y abdominal Asian: presented with seizures and localising signs
- Background of weight loss, dry cough and fever for 12w
- HIV confirmed: CD4 3, Viral load 292000 – treated as TP





Oral lesions noted

- Biopsy: budding yeasts
- Culture – histoplasma capsulatum
- Treatment AMP-B
- Response good







IRS can occur





Patient 7

- Presented with PCP
  - ITU and bilateral pneumothoraces
  - CD4 2, VL >1million
- Retina
  - CMV retinitis
- Sputum
  - Aspergillus
- Blood/sputum
  - MAI



Slow but steady response

- OI treatment:
  - PCP: COT/steroids
  - CMV: ganciclovir
  - Aspergillus: Voriconazole
  - MAI: azithromycin, ethambutol, moxifloxacin, linezolid
- HIV treatment:
  - Raltegravir, Truvada



Outline

- Differing knowledge and differing requirements…
- Today I will break it down:
  - Review of many of the OI's
  - Focus on the main clinical challenges
  - Present recent data
- Hopefully you interrupted!

Thanks

Patient 3

- 42y old man, partner diagnosed HIV+ve so has test also +ve
- Asymptomatic, CD4 46
- Starts HAART with EFV/ABC/ 3TC
- 2w CNS s/e attributed to EFV
- 8w later bizarre behaviour
- Diminished cognitive function, withdrawn affect. No obvious localising signs
- CT scan



Patient 3

- 42y old man, partner diagnosed HIV+ve so has test also +ve
- Asymptomatic, CD4 46
- Starts HAART with EFV/ABC/ 3TC
- 2w CNS s/e attributed to EFV
- 8w later bizarre behaviour
- Diminished cognitive function, withdrawn affect. No obvious localising signs
- MR scan
- **CSF:**
  - **no cells, normal protein & glucose ratio**
  - **RPR and India ink –ve**
  - **JC strongly +ve**



What are the challenges

A. Diagnosis
B. Place of brain biopsy?
C. Treatment
D. Research

A. Diagnosis - Imaging

MR FEATURES			
	PML		TOXOPLASMOSIS
Number	Single-multiple		Usually multiple
Enhancement	Nil		Prominent Ring
Oedema	Nil		Marked
Location	Occipitoparietal		Basal ganglia Brain stem Cortical
	White matter		Interface grey-white matter
MR T1	Low signal		Low signal
MR T2	High signal		High signal



Diagnosis - CSF

- The presence of JC virus found in CSF by PCR technique
  - Sensitivity of >90% (<60% if on HAART)
  - Specificity of 96 to 98 %
- No help in blood
  - JC PCR in blood in 30 to 40 % of normal population



B. Place of brain biopsy?

- Brain biopsy has been the accepted diagnostic method
- However, typical NMR scan + JC PCR positive on CSF is highly specific and is now accepted
- **Consider if:**
  - PCR negative
  - Multiple areas or atypical appearanc
  - High CD4 or on established HAART
  - PCR positive with atypical NMR
  - Confirmed other CNS diagnosis



C. Treatment

- 1st line:
  - **HAART**
  - Cidofovir no benefit
- IRS:
  - Well described
  - Most often on ‘unmasking’ when worse prognosis

D. Continued research – mefloquine ineffective

RCT
SOC vs. MF



Thank you

For further information please contact :

Jean-Marc Debricon
CEO
jm@greenshootsfoundation.org
Mobile: +44 7595 600 766

Green Shoots Foundation
P.O. Box 63678
London, SW11 9BD
UK

UK charity number 1138412 US 501(c)(3) registered

General enquiries: info@greenshootsfoundation.org
Website: www.greenshootsfoundation.org

GreenShoots
FOUNDATION